Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

NCT05625087 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

162

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Stage IV

Interventions

DRUG: Alpelisib
DRUG: Ribociclib

Sponsor

UNICANCER

Collaborators

[object Object]
[object Object]